For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | - | 0* | - | - |
| Research and development | 343,970 | 254,651* | 262,506 | 224,134 |
| General and administrative | 101,252 | 55,023* | 52,763 | 40,580 |
| Total operating expenses | 445,222 | 309,673* | 315,269 | 264,714 |
| Loss from operations | -445,222 | -309,673* | -315,269 | -264,714 |
| Interest income | 19,508 | 8,142* | 22,083 | 22,404 |
| Interest and other income (expense), net | - | - | - | -899 |
| Interest expense | 12,197 | -10,053* | 11,428 | - |
| Change in fair value of warrant liability and contingent earn-out shares | - | -7,603* | -592 | -4,578 |
| Change in fair value of warrant liability | 15,788 | - | - | - |
| Other expense, net | - | 9* | - | - |
| Other income (expense), net | 117 | - | 0 | - |
| Total non-operating income (expense), net | -8,594 | 10,583* | 10,063 | 16,927 |
| Loss before income taxes | -453,816 | -299,090* | -305,206 | -247,787 |
| Benefit from income taxes | - | 0* | - | - |
| Net loss | -453,816 | -299,090* | -305,206 | -247,787 |
| Unrealized loss on investments, net | - | -3,526* | 1,814 | - |
| Comprehensive loss | - | -302,616 | -303,392 | - |
| Basic EPS | -2.29 | -1.571 | -1.61 | -1.31 |
| Diluted EPS | -2.29 | -1.571 | -1.61 | -1.31 |
| Basic Average Shares | 198,098,047 | 192,572,612 | 189,231,562 | 188,583,288 |
| Diluted Average Shares | 198,098,047 | 192,572,612 | 189,231,562 | 188,583,288 |
Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. (RVMD)